


We Claim:

1. A compound of Formula I




5

**Formula I**

or a pharmaceutically acceptable salt thereof wherein:

A is structure i, ii, iii, or iv;



10

wherein the dashed line in formula iii represents an optional double bond;

n is 0 or 1;

X is O, S, NH, Nalkyl, NOH, and NOalkyl;

Z is  $\text{NHC}(=\text{O})\text{R}^1$ ,  $\text{NHC}(=\text{S})\text{R}^1$ ,  $\text{C}(=\text{O})\text{NHR}^1$ ,  $\text{C}(=\text{O})\text{N}(\text{H})\text{OH}$ ,

$\text{NHC}(=\text{NCN})\text{R}^1$ ,  $\text{NH-het}^1$ ,  $\text{O-het}^1$ ,  $\text{S-het}^1$ , or  $\text{het}^2$ ;

15

$\text{R}^1$  is H,  $\text{NH}_2$ ,  $\text{NHC}_{1-4}\text{alkyl}$ ,  $\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{2-4}\text{alkenyl}$ ,  $-(\text{CH}_2)_m\text{C}(=\text{O})\text{C}_{1-4}\text{alkyl}$ ,  $\text{OC}_{1-4}\text{alkyl}$ ,  $\text{SC}_{1-4}\text{alkyl}$ ,  $(\text{CH}_2)_m\text{C}_{3-6}\text{cycloalkyl}$ ,  $\text{CH}=\text{CH-aryl}$ ,  $\text{CH}=\text{CH-het}^1$ ,  $\text{CH}_2\text{C}(=\text{O})\text{-aryl}$ , or  $\text{CH}_2\text{C}(=\text{O})\text{-het}^1$ , the alkyl, aryl or het optionally being a substituted alkyl, substituted aryl or substituted het, respectively;

$\text{R}^2$  and  $\text{R}^3$  are independently H or F;

20

$\text{R}^4$  is H, Cl, F,  $\text{CH}_3$ ,  $\text{CF}_3$ ,  $\text{NH}_2$ ,  $\text{NO}_2$  or CN;

$\text{R}^5$  and  $\text{R}^6$  are independently H, alkyl, substituted alkyl, -Salkyl, -Oalkyl, alkenyl, substituted alkenyl, hydroxy, aryl, or halo;

$\text{R}^7$  is H, alkyl, substituted alkyl, cycloalkyl,  $\text{C}(=\text{O})\text{alkyl}$ ,  $\text{C}(=\text{O})\text{substituted alkyl}$ , aryl, alkenyl, substituted alkenyl, het, substituted het, or substituted aryl;


25

$\text{het}^1$  is a C-linked five- (5) or six- (6) membered heterocyclic ring which contains 1-4 heteroatoms selected from oxygen, sulfur, and nitrogen;

$\text{het}^2$  is a N- or C-linked five- (5) or six- (6) membered heterocyclic ring which contains 1-4 heteroatoms selected from oxygen, sulfur, and nitrogen;

each m is independently 0, 1 or 2.

2. The compound of claim 1, wherein A is



5

3. The compound of claim 1, wherein R<sub>7</sub> is alkyl or substituted alkyl.

4. The compound of claim 1, wherein R<sub>5</sub> is halo.


- 10 5. The compound of claim 4, wherein R<sub>6</sub> is halo.

6. The compound of Claim 1 selected from the group:

- a) (5*R*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;
- 15 b) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;
- c) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;
- d) (5*R*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;
- 20 e) N-[[[(5*S*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide; and
- f) N-[[[(5*S*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide.

25

7. A compound of Formula II




wherein:

$R^7$  is alkyl of 1 to 4 carbons;

M is selected from the group consisting of  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHC(O)OR}^8$ , or

5 structure i



i ;

wherein  $R^8$  is alkyl of 1 to 4 carbons or benzyl.

8. The compound of claim 7, wherein  $R_7$  is alkyl or substituted alkyl.

10

9. The compound of Claim 7 selected from the group:

a) butyl (5R)-3-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinecarboxylate;

15

b) benzyl 1-ethyl-3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-5-ylcarbamate;

c) 5-amino-1-ethyl-3,3-difluoro-1,3-dihydro-2H-indol-2-one;

d) 1-ethyl-3,3-difluoro-5-nitro-1,3-dihydro-2H-indol-2-one;

e) benzyl 3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1H-indol-5-ylcarbamate;

20

f) 5-amino-3,3-difluoro-1-methyl-1,3-dihydro-2H-indol-2-one;

g) 3,3-difluoro-1-methyl-5-nitro-1,3-dihydro-2H-indol-2-one; and

h) butyl (5R)-3-(3,3-difluoro-1-ethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinecarboxylate.

25

10. Use of a compound of claim 1 or 7 for preparing a medicament for treating microbial infections in mammals.

11. The use of claim 10, wherein the medicament is prepared for administration orally, parenterally, transdermally, or topically.

5

12. The use of claim 10, wherein the medicament includes from about 0.1 to about 1000 mg of the compound of claim 1 or 7.

13. The use of claim 10, wherein the medicament includes from about 0.1 to about  
10 500 mg of the compound of claim 1 or 7.

14. A pharmaceutical composition comprising a compound of claim 1 or 7 and a pharmaceutically acceptable carrier.